Janus Henderson Investors US’s Trinity Biotech TRIB Stock Holding History

Janus Henderson Investors US’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$8.45M	Sell	9,454 -16	-0.2%	-$15K	0.01%	723
2016 Q4	$9.83M	Sell	9,470 -51	-0.5%	-$52.7K	0.01%	722
2016 Q3	$18.9M	Sell	9,521 -26	-0.3%	-$48.6K	0.02%	601
2016 Q2	$16.2M	Buy	9,547 +120	+1%	+$203K	0.01%	602
2016 Q1	$16.5M	Sell	9,427 -104	-1%	-$166K	0.01%	602
2015 Q4	$16.8M	Buy	9,531 +1,878	+25%	+$3.33M	0.01%	630
2015 Q3	$13.1M	Buy	7,653 +4,153	+119%	+$10M	0.01%	672
2015 Q2	$9.48M	Buy	+3,500	New	+$9.09M	0.01%	711

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Janus Henderson Investors US's TRIB Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Trinity Biotech (TRIB) stake by 0.17% in Q1 2017, selling an estimated $15K and leaving 9,454 shares worth $8.45M. The position accounts for 0.01% of the portfolio, ranked #723.

Janus Henderson Investors US first reported a position in TRIB in Q2 2015 and has held it in 8 quarters since. The position peaked at $18.9M in Q3 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

Janus Henderson Investors US held 9,454 shares of Trinity Biotech worth $8.45M as of Q1 2017.
Janus Henderson Investors US sold 16 Trinity Biotech shares in Q1 2017, an estimated $15K.
Trinity Biotech made up 0.01% of Janus Henderson Investors US's portfolio in Q1 2017, its #723 holding.
Janus Henderson Investors US first reported a position in Trinity Biotech in Q2 2015 and has held it in 8 quarters since.
Janus Henderson Investors US's Trinity Biotech position peaked at $18.9M in Q3 2016.
67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.